首页>The Journal of Nuclear Medicine>Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin
Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin
作者单位：Bayer Pharma AG, Global Drug Discovery, Berlin, Germany[1]Department of Pathology, University Hospital Bern, Bern, Switzerland[2]Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany[3]Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany, Institute of Nuclear[4]Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany, Department of Radiology[5]Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland[6]
换一批
